Drug Approval | June 22, 2024
Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
This approval has come from the company's finished dosage form manufacturing facility
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Subscribe To Our Newsletter & Stay Updated
